A P1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG and Followed by Treatment With Extended-Release 5-FC

Trial Profile

A P1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG and Followed by Treatment With Extended-Release 5-FC

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Vocimagene amiretrorepvec-flucytosine gene therapy (Primary)
  • Indications Glioblastoma; Glioma
  • Focus Adverse reactions
  • Sponsors Tocagen
  • Most Recent Events

    • 23 Feb 2017 According to a Tocagen media release, the U.S. Food and Drug Administration (FDA) has granted Toca 511 & Toca FC Breakthrough Therapy Designation for the treatment of patients with recurrent high grade glioma (HGG). Data from this study supported the application.
    • 05 Oct 2016 According to Tocagen media release, the company presented the efficacy data of evaluable subset at the 10th International Oncolytic Virus Meeting.
    • 05 Oct 2016 Results were published in the Tocagen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top